Concerta (methylphenidate OROS) and Strattera (atomoxetine) treat ADHD through fundamentally different mechanisms: Concerta is a controlled-substance stimulant, and Strattera is a non-stimulant with no abuse potential and no controlled-substance schedule. This guide compares how each delivers its dose over the day, their approved uses, onset of effect, and their very different boxed warnings.
This is general information, not medical advice.
Concerta vs Strattera at a glance
| Concerta (methylphenidate) | Strattera (atomoxetine) | |
|---|---|---|
| Drug class | CNS stimulant | Selective norepinephrine reuptake inhibitor (non-stimulant) |
| Controlled substance | Schedule II | Not a controlled substance |
| FDA-approved for | ADHD | ADHD |
| Onset of effect | Within hours of the first dose | Full benefit may take several weeks |
| Boxed warning | Abuse, misuse, and addiction | Suicidal ideation in children and adolescents |
| Delivery mechanism | OROS osmotic pump, once-daily | Standard capsule, once or twice daily |
What each is approved for
Both are approved for ADHD, and only ADHD; neither has a comparable secondary indication in this comparison. The meaningful difference is not what they treat, but how they work and what class of risk they carry.
How Concerta delivers its dose: the OROS system
Concerta uses a delivery technology called OROS (osmotic-controlled release oral delivery system). The label explains that mean methylphenidate plasma concentrations after a single Concerta dose show a gradual increase, with peak concentrations occurring between 6 and 10 hours after the dose, rather than the sharp peak-and-trough pattern of immediate-release methylphenidate taken multiple times a day.
A pharmacokinetic study comparing OROS methylphenidate 18 mg once daily, sustained-release methylphenidate, and immediate-release methylphenidate given three times a day found that OROS produced a gradual rise with peak concentrations at 6 to 8 hours, while the immediate-release regimen’s levels fluctuated in tandem with each dose. The label states plainly that Concerta once daily minimizes the fluctuations between peak and trough concentrations associated with immediate-release methylphenidate three times daily, while producing no clinically significant difference in overall methylphenidate exposure between the two approaches. In practice, this means Concerta aims to deliver smoother, more even coverage across the school or work day from a single morning dose, rather than requiring a lunchtime dose at school.
How Strattera works: no stimulant effect at all
Strattera (atomoxetine) is not a stimulant. Its label describes it as a selective norepinephrine reuptake inhibitor, meaning it primarily affects norepinephrine rather than the dopamine-heavy mechanism stimulants use. Because it lacks stimulant activity, it is not scheduled as a controlled substance, has no meaningful abuse potential, and does not carry the abuse-related boxed warning that every stimulant ADHD drug carries.
The tradeoff is speed. Strattera’s clinical benefit typically develops over several weeks, unlike stimulants, which produce a noticeable effect within hours of the first appropriately titrated dose. Patients and families should be told to expect a slower ramp-up, and dosing is often started low and increased gradually.
The two very different boxed warnings
Concerta’s boxed warning is for abuse, misuse, and addiction, the standard warning across CNS stimulants: high potential for abuse and misuse that can lead to a substance use disorder, and misuse or abuse of CNS stimulants can result in overdose and death, with risk increasing at higher doses or with unapproved methods of administration.
Strattera’s boxed warning is entirely different: it increased the risk of suicidal ideation in short-term studies in children and adolescents with ADHD. The label also carries specific warnings about severe liver injury, requiring discontinuation and no restarting if jaundice or laboratory evidence of liver injury appears, and about serious cardiovascular events, including sudden death, stroke, and myocardial infarction reported in association with atomoxetine treatment.
These are not interchangeable risks. A family choosing between the two is weighing a stimulant abuse/misuse and cardiovascular risk profile against a non-stimulant profile carrying its own suicidality, liver, and cardiovascular warnings. Neither is risk-free, and the right choice depends heavily on individual and family history.
Dosing
Concerta is given once daily in the morning, with or without food, swallowed whole (never chewed, divided, or crushed, since that would defeat the OROS mechanism). For patients new to methylphenidate, pediatric patients 6 to 17 start at 18 mg once daily, increased weekly in 18 mg increments up to a maximum of 54 mg (ages 6-12) or 72 mg (ages 13-17); adults up to 65 start at 18 or 36 mg once daily, increasing up to 72 mg.
Strattera dosing is weight-based in children and adolescents, generally started low and titrated over about 2 to 4 weeks to an effective maintenance dose, given once daily in the morning or split into a morning and late-afternoon/early-evening dose if better tolerated.
Drug interactions
Strattera’s levels rise significantly when combined with CYP2D6 inhibitors (such as certain SSRIs including fluoxetine and paroxetine), which can require a lower Strattera dose. It should also be used cautiously with antihypertensive drugs and pressor agents because of its effects on blood pressure and heart rate. Concerta interacts with MAOIs (contraindicated) and can affect blood pressure medications’ effectiveness.
Who each might suit
Factors that may point toward Concerta:
- A need for rapid, same-day symptom control
- No personal or family history of substance use disorder that would raise particular concern about a controlled stimulant in the household
- Comfort with once-daily dosing timed to the OROS release profile
Factors that may point toward Strattera:
- A history of substance use disorder in the patient or household, where a non-stimulant, non-controlled option is preferred
- Co-occurring tic disorders, which stimulants can sometimes worsen
- A family and prescriber comfortable with a slower onset of benefit in exchange for avoiding stimulant-specific risks
- Close monitoring already in place for mood symptoms, given the suicidality warning that requires vigilance regardless of drug choice
Frequently asked questions
Why does Concerta only need to be taken once a day?
Its OROS delivery system releases methylphenidate gradually over hours, producing a smoother plasma level curve than immediate-release methylphenidate taken multiple times daily, with peak concentrations occurring 6 to 10 hours after the dose.
Is Strattera a stimulant?
No. It is a selective norepinephrine reuptake inhibitor and is not a controlled substance, unlike Concerta and other stimulant ADHD medicines.
How long does Strattera take to work?
Full benefit can take several weeks, unlike stimulants, which typically show an effect within hours of an appropriately dosed first day.
What is Strattera’s most serious warning?
Its boxed warning covers an increased risk of suicidal ideation in children and adolescents. It also carries specific warnings about severe liver injury and serious cardiovascular events.
Can I crush a Concerta tablet?
No. It must be swallowed whole. Crushing, chewing, or dividing it defeats the OROS release mechanism and could cause a rapid, unintended release of the full dose.
Can Concerta and Strattera be combined?
Yes — this is actually a common clinical strategy rather than an either/or choice in every case. Some prescribers combine a stimulant like Concerta with a non-stimulant like Strattera when a single agent doesn’t fully control symptoms, or to extend coverage into the evening without adding more stimulant medication late in the day (since Strattera is not a controlled substance and doesn’t carry the same insomnia-triggering late-dose concern in the same way stimulants do). Any combination should be initiated and monitored by the prescribing clinician given the cardiovascular and psychiatric warnings attached to both drugs individually.
Growth and long-term pediatric monitoring
Both drugs require monitoring in children. Stimulants, including Concerta, are associated with modest decreases in expected weight and height gain during long-term use, tracked via routine growth charting at follow-up visits. Strattera’s label similarly recommends monitoring height and weight during treatment, and both require baseline and periodic cardiovascular assessment (heart rate, blood pressure) given each drug’s effects on these measures. Neither is considered inherently “safer” for the heart; they carry different but real cardiovascular considerations.
What if Concerta stops working during the day?
Because Concerta’s OROS mechanism is not adjustable once swallowed, if a patient consistently loses coverage before the end of the day, the options are generally a dose increase, an earlier morning dosing time, or a switch to a different delivery system entirely (twice-daily immediate-release methylphenidate, or a different molecule such as amphetamine-based options). This “wearing off” pattern is a known limitation of any single fixed-release product and is one of the more common reasons for adjusting a stimulant regimen over time.
Strattera’s slower onset in practice
Because Strattera’s benefit builds over roughly 2 to 6 weeks rather than appearing on day one, clinicians typically advise families not to judge its effectiveness within the first week or two, and not to increase the dose faster than the label’s titration schedule just because early results seem underwhelming. This delayed-onset pattern is one of the most common sources of early discontinuation, so setting expectations correctly at the start of treatment matters as much as the prescribing decision itself.
Frequently asked questions (continued)
Can Concerta and Strattera be taken together?
Some prescribers do combine them for additional or extended symptom coverage, but this should only be done under medical supervision given the warnings attached to each drug.
Why did Concerta stop working as well after a few months?
Tolerance, growth, dose need changes over time, or simply reaching the ceiling of what a fixed-release product can cover are all possible; this is a reason to follow up with the prescriber rather than to adjust the dose independently.
How long should I wait to know if Strattera is working?
Clinical guidance generally suggests giving it several weeks, often cited as up to 6 weeks, before judging its full effect, since its benefit builds gradually rather than appearing immediately like a stimulant would.
Why non-controlled status matters practically, not just legally
Because Strattera is not a controlled substance, prescriptions can typically be called in or refilled with fewer restrictions than Schedule II stimulants like Concerta, which in the US generally cannot be phoned in, cannot be refilled without a new written (or state-specific electronic) prescription each time, and are subject to stricter prescribing limits and monitoring under state prescription drug monitoring programs. For families managing a child’s ongoing ADHD treatment, this translates into a real day-to-day convenience difference: fewer pharmacy trips, fewer scheduling headaches around 30-day supply limits, and no need to store a controlled substance securely at home in the same way. This is separate from, but related to, the abuse-potential difference discussed earlier.
Tic disorders and Tourette syndrome
One specific clinical scenario where the Concerta-vs-Strattera decision is more clear-cut: patients with a co-occurring tic disorder or Tourette syndrome alongside ADHD. Stimulants, including Concerta, have historically been associated with a theoretical risk of exacerbating tics in susceptible patients, though later research on this relationship is more nuanced and not universally confirmatory. Because Strattera is not a stimulant, prescribers often reach for it, or another non-stimulant, preferentially in patients with a significant tic history, though this remains an individualized clinical judgment made case by case rather than an absolute rule.
Appetite and growth effects in practice
Parents often notice reduced appetite during the school day with Concerta, sometimes prompting a “eat dinner, not lunch” pattern that clinicians are used to managing by encouraging a bigger breakfast before the dose and a substantial evening meal once the medication wears off. Strattera’s appetite-suppression profile tends to be milder for many patients, though it is not appetite-neutral either, and its own label lists decreased appetite among common adverse reactions in pediatric trials.
Frequently asked questions (continued, second round)
Is it harder to get a Concerta refill than a Strattera refill?
Generally yes. As a Schedule II controlled substance, Concerta prescriptions face stricter refill and prescribing rules than Strattera, which is not a controlled substance.
Can Concerta make tics worse?
Stimulants have historically been associated with a theoretical risk of worsening tics in susceptible patients, though the evidence is mixed. This is one scenario where a non-stimulant like Strattera is sometimes preferred.
Does Strattera suppress appetite as much as Concerta?
Many patients find Strattera’s appetite effect milder than a stimulant’s, though it is still a listed common side effect and not appetite-neutral.
Practical tips for starting either medication
- Give Strattera the full titration period before judging effectiveness; stopping in week two because “nothing happened” is the most common preventable reason families abandon a drug that would have worked.
- Take Concerta at a consistent morning time; a swallowed-whole dose that varies by hours day to day makes it harder to judge whether afternoon symptom return is a true wearing-off or just a later start.
- Watch mood closely in the first weeks of either drug, especially in adolescents, given Strattera’s boxed suicidality warning and the general recommendation to monitor any new psychiatric medication in this age group closely.
- Report any yellowing of skin or eyes, unusual fatigue, or dark urine to a prescriber immediately while on Strattera, given its liver injury warning.
- Keep blood pressure and heart rate checks on schedule with both drugs; these are routine, not optional, parts of monitoring either treatment.
References
- FDA. CONCERTA (methylphenidate hydrochloride) extended-release tablets, prescribing information (2026).
- Modi NB, et al. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. Journal of Clinical Pharmacology, 2000 (PubMed).
- DailyMed. STRATTERA (atomoxetine) capsules, prescribing information.
- FDA. Atomoxetine (marketed as Strattera) information.